InfuSystem (INFU) Investor presentation summary

Financial performance and growth

• Achieved six consecutive years of record revenue, reaching $134.9M in 2024, with a 12% revenue CAGR and 11% adjusted EBITDA CAGR since 2019.

• 2024 adjusted EBITDA was $25.3M, with substantial annual cash flow of $20.5M from operations.

• Maintained a solid balance sheet with a net leverage ratio of 0.66x and debt/equity ratio of 0.78x as of September 30, 2025.

• Gross margin remained strong, with patient services at 65.1% and device solutions at 44.8% in 2024.

• Capital expenditures and revenue growth have been managed to sustain optimal CapEx efficiency.

Business model and operations

• Operates a fleet of over 100,000 devices, serving 19 of the top 20 hospital systems and over 2,000 care sites in the U.S. and Canada.

• Patient services segment (60% of 2024 revenue) focuses on outpatient care, while device solutions (40%) provides equipment and services to providers.

• Participates in over 800 health insurance networks, covering more than 96% of the U.S. population.

• Offers device-agnostic services, 24/7 patient support, and a white-glove concierge approach in device solutions.

• Employs more than 500 staff across seven major service areas.

Strategic initiatives and partnerships

• Expanded into new therapies and partnerships, leveraging oncology expertise for growth in pain management and wound care.

• Recent agreements include national distribution with Genadyne, Smith+Nephew, Solo-Dex, Sanara MedTech, Cork Medical, and ChemoMouthpiece.

• Biomedical services and wound care identified as major growth drivers.

• Ongoing process enhancements aim to boost net margins and sustain growth.